Acquired carbapenemase-producing Gram-negative bacteria are an increasing public health concern globally and have been mandatory to report in England since October 2020. However, in light of the COVID-19 (SARS-CoV-2) pandemic, the Royal College of Pathologists (RCPath) released new guidance “for reducing the need for screening of CRE (carbapenem-resistant Enterobacterales) […] in low-risk areas”, without defining “low risk”. To assess the impact of the RCPath recommendations on screening of carbapenemase-producing Enterobacterales (CPE), an online Select Survey was sent to all NHS acute hospitals in England. The initial survey distribution was between March and April 2021 and the survey was relaunched between November 2021 and March 2022. In total, 54 hospitals completed the survey, representing 39.1% of 138 eligible Trusts. All hospitals had a CPE screening policy in place, and the majority of these reflect UKHSA's Framework of actions to contain CPE. Of the 23 hospitals who reported a reduction in CPE screening, only three (13.0%) indicated that this was due to the RCPath recommendations, with 21 (91.3%) indicating that there had been a natural reduction in the number of patients admitted to the Trust who would have previously been screened due to the COVID-19 pandemic. For most surveyed hospitals, CPE screening was not reduced due to the RCPath recommendations. However, the results highlighted that there is a large amount of individual variation in CPE screening practices and diagnostic testing between hospitals.
England, like other countries that experienced a large outbreak of emergent mpox in 2022, continued to record cases during 2023 at a low but steady frequency. Comprehensive national surveillance shows that cases continue to occur primarily among gay, bisexual and other men who have sex with men mostly in London. Of 137 cases in 2023, around half were acquired overseas, half were vaccinated, and one case of reinfection was reported. Eleven people required hospital care. High vaccination uptake, during 2022, has provided good coverage of those at higher risk of mpox. Using the screening method, vaccine effectiveness of one dose was estimated at 84%. None of the vaccinated cases in 2023 were hospitalised.
The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) antimicrobial resistance (AMR) chapter reports on bacterial, viral, and fungal AMR trends between 2017 and 2021 in England. A 10.8% increase in patient episodes of bacteraemia or fungaemia was observed, and the estimated burden of resistance decreased by 4.2%. Individuals with an antimicrobial-resistant strain (resistant to ≥1 key AMR burden-defined antibiotics) had a higher crude case fatality rate (18.1%) compared to those with a susceptible strain (16.3%). The effect of deprivation on carbapenemase-producing organisms (CPO) incidence, and the impact of the AMR burden across ethnic groups, have been described for the first time. Understanding the impact of ethnicity, deprivation, regional divergence, and potential confounders remains a crucial avenue of enquiry to target appropriate AMR interventions. These findings were presented at the ESPAUR Report webinar on 23 November 2022.
24 March 2026 in International Journal of STD & AIDS
Background: Mycoplasma genitalium is a sexually transmitted pathogen of public health concern due to antimicrobial resistance to the recommended first- and second-line treatments, azithromycin and moxifloxacin. The M. genitalium Antimicrobial Resistance Surveillance (MARS) programme monitors resistance trends in England to inform clinical management and public health policy. Here, we summarise key findings from MARS 2024. Methods: From 1 st March to 30 th June 2024, M. genitalium -positive specimens were collected at 32 sentinel sexual health services across England. Specimens were tested for molecular markers predictive of macrolide and fluoroquinolone resistance in the 23S rRNA and parC genes, respectively. In non-wildtype parC specimens, the gyrA gene was also sequenced. AMR data were linked to patient demographic, clinical, and behavioural data. Results: The MARS 2024 sample included 1,049 individuals; 65.6% were male. Where resistance results were available, 63.6% of specimens were macrolide-resistant, 16.7% were fluoroquinolone resistant, and 13.7% were dual-resistant to both antimicrobials. Compared to MARS 2023, high levels of macrolide resistance remain, with increasing fluoroquinolone ( p = 0.008) and dual resistance ( p = 0.024). Most individuals (87.3%) were prescribed the recommended first- or second-line treatments and 80.8% received doxycycline as a pre-treatment. Resistant genotypes were common among those with a positive test-of-cure (TOC): 90.9% of individuals with a positive TOC following azithromycin were infected with a macrolide-resistant strain, and 51.6% of those with a positive TOC following moxifloxacin were infected with a fluoroquinolone-resistant strain. However, genotype did not consistently predict TOC outcome, as 14.6% of those with negative TOCs following azithromycin had macrolide-resistant infections and 16.6% of those with negative TOCs following moxifloxacin had fluoroquinolone-resistant infections. Conclusions: MARS 2024 is the largest dataset examining antimicrobial resistance in M. genitalium in England, confirming widespread macrolide resistance and increasing levels of fluoroquinolone and dual resistance, underscoring the importance of national surveillance to inform management guidelines.